|
1
|
Negro R, Gobessi S, Longo PG, He Y, Zhang
ZY, Laurenti L and Efremov DG: Overexpression of the
autoimmunity-associated phosphatase PTPN22 promotes survival of
antigen-stimulated CLL cells by selectively activating AKT. Blood.
119:6278–6287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oi T, Asanuma K, Matsumine A, Matsubara T,
Nakamura T, Iino T, Asanuma Y, Goto M, Okuno K, Kakimoto T, et al:
STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for
osteosarcoma. Int J Oncol. 49:2275–2284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fecteau JF, Messmer D, Zhang S, Cui B,
Chen L and Kipps TJ: Impact of oxygen concentration on growth of
mesenchymal stromal cells from the marrow of patients with chronic
lymphocytic leukemia. Blood. 121:971–974. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rawstron AC, Böttcher S, Letestu R,
Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M,
Moreno C, et al: European Research Initiative in CLL: Improving
efficiency and sensitivity: European Research Initiative in CLL
(ERIC) update on the international harmonised approach for flow
cytometric residual disease monitoring in CLL. Leukemia.
27:142–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Samuel S, Beljanski V, Van Grevenynghe J,
Richards S, Ben Yebdri F, He Z, Nichols C, Belgnaoui SM, Steel C,
Goulet ML, et al: BCL-2 inhibitors sensitize therapy-resistant
chronic lymphocytic leukemia cells to VSV oncolysis. Mol Ther.
21:1413–1423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fang C, Zhuang Y, Wang L, Fan L, Wu YJ,
Zhang R, Zou ZJ, Zhang LN, Yang S, Xu W, et al: High levels of CD20
expression predict good prognosis in chronic lymphocytic leukemia.
Cancer Sci. 104:996–1001. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soroosh P and Doherty TA: Th9 and allergic
disease. Immunology. 127:450–458. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tete S, Saggini A, Maccauro G, Rosati M,
Conti F, Cianchetti E, Tripodi D, Toniato E, Fulcheri M, Salini V,
et al: Interleukin-9 and mast cells. J Biol Regul Homeost Agents.
26:319–326. 2012.PubMed/NCBI
|
|
9
|
Hornakova T, Staerk J, Royer Y, Flex E,
Tartaglia M, Constantinescu SN, Knoops L and Renauld JC: Acute
lymphoblastic leukemia-associated JAK1 mutants activate the Janus
kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J
Biol Chem. 284:6773–6781. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fionda C, Malgarini G, Soriani A, Zingoni
A, Cecere F, Iannitto ML, Ricciardi MR, Federico V, Petrucci MT,
Santoni A, et al: Inhibition of glycogen synthase kinase-3
increases NKG2D ligand MICA expression and sensitivity to NK
cell-mediated cytotoxicity in multiple myeloma cells: Role of
STAT3. J Immunol. 190:6662–6672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY,
Qiu MZ, Ren C, Zhang DS, Wang ZQ, Wang FH, et al: Overexpression of
paxillin induced by miR-137 suppression promotes tumor progression
and metastasis in colorectal cancer. Carcinogenesis. 34:803–811.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk
ML and Struhl K: STAT3 activation of miR-21 and miR-181b-1 via PTEN
and CYLD are part of the epigenetic switch linking inflammation to
cancer. Mol Cell. 39:493–506. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura H, Taguchi A, Kawana K, Kawata A,
Yoshida M, Fujimoto A, Ogishima J, Sato M, Inoue T, Nishida H, et
al: STAT3 activity regulates sensitivity to tumor necrosis
factor-related apoptosis-inducing ligand-induced apoptosis in
cervical cancer cells. Int J Oncol. 49:2155–2162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hartman ML and Kilianska ZM: Lipoprotein
lipase: A new prognostic factor in chronic lymphocytic leukaemia.
Contemp Oncol (Pozn). 16:474–479. 2012.PubMed/NCBI
|
|
16
|
ENCODE Project Consortium, . Myers RM,
Stamatoyannopoulos J, Snyder M, Dunham I, Hardison RC, Bernstein
BE, Gingeras TR, Kent WJ, Birney E, Wold B, et al: A user's guide
to the encyclopedia of DNA elements (ENCODE). PLoS Biol.
9:e10010462011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen N, Lv X, Li P, Lu K and Wang X: Role
of high expression of IL-9 in prognosis of CLL. Int J Clin Exp
Pathol. 7:716–721. 2014.PubMed/NCBI
|
|
18
|
Chen N, Lu K, Li P, Lv X and Wang X:
Overexpression of IL-9 induced by STAT6 activation promotes the
pathogenesis of chronic lymphocytic leukemia. Int J Clin Exp
Pathol. 7:2319–2323. 2014.PubMed/NCBI
|
|
19
|
Barski A, Cuddapah S, Cui K, Roh TY,
Schones DE, Wang Z, Wei G, Chepelev I and Zhao K: High-resolution
profiling of histone methylations in the human genome. Cell.
129:823–837. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Petrus M, Bryant BR, Nguyen Phuc
V, Stamer M, Goldman CK, Bamford R, Morris JC, Janik JE and
Waldmann TA: Induction of the IL-9 gene by HTLV-I Tax stimulates
the spontaneous proliferation of primary adult T-cell leukemia
cells by a paracrine mechanism. Blood. 111:5163–5172. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsushita K, Arima N, Ohtsubo H, Fujiwara
H, Hidaka S, Fukumori J and Tanaka H: Frequent expression of
interleukin-9 mRNA and infrequent involvement of interleukin-9 in
proliferation of primary adult T-cell leukemia cells and HTLV-I
infected T-cell lines. Leuk Res. 21:211–216. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U,
Bryant BR, Chen J, Sato N, Tagaya Y, Morris JC, et al: CP-690,550,
a therapeutic agent, inhibits cytokine-mediated Jak3 activation and
proliferation of T cells from patients with ATL and HAM/TSP. Blood.
117:1938–1946. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schuringa JJ, Wierenga AT, Kruijer W and
Vellenga E: Constitutive Stat3, Tyr705, and Ser727 phosphorylation
in acute myeloid leukemia cells caused by the autocrine secretion
of interleukin-6. Blood. 95:3765–3770. 2000.PubMed/NCBI
|
|
24
|
Brender C, Nielsen M, Kaltoft K, Mikkelsen
G, Zhang Q, Wasik M, Billestrup N and Odum N: STAT3-mediated
constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
Blood. 97:1056–1062. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steele AJ, Prentice AG, Cwynarski K,
Hoffbrand AV, Hart SM, Lowdell MW, Samuel ER and Wickremasinghe RG:
The JAK3-selective inhibitor PF-956980 reverses the resistance to
cytotoxic agents induced by interleukin-4 treatment of chronic
lymphocytic leukemia cells: Potential for reversal of
cytoprotection by the microenvironment. Blood. 116:4569–4577. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goswami R, Jabeen R, Yagi R, Pham D, Zhu
J, Goenka S and Kaplan MH: STAT6-dependent regulation of Th9
development. J Immunol. 188:968–975. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rozovski U, Calin GA, Setoyama T, D'Abundo
L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, et
al: Signal transducer and activator of transcription (STAT)-3
regulates microRNA gene expression in chronic lymphocytic leukemia
cells. Mol Cancer. 12:502013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li P, Grgurevic S, Liu Z, Harris D,
Rozovski U, Calin GA, Keating MJ and Estrov Z: Signal transducer
and activator of transcription-3 induces microRNA-155 expression in
chronic lymphocytic leukemia. PLoS One. 8:e646782013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shaim H, Estrov Z, Harris D, Sanabria
Hernandez M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M,
Burger J, et al: The CXCR4-STAT3-IL-10 pathway controls the
immunoregulatory function of chronic lymphocytic leukemia and is
modulated by lenalidomide. Front Immunol. 8:17732018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He S, Liao G, Liu Y, Huang L, Kang M and
Chen L: Overexpression of STAT3/pSTAT3 was associated with poor
prognosis in gastric cancer: A meta-analysis. Int J Clin Exp Med.
8:20014–20023. 2015.PubMed/NCBI
|
|
31
|
Carretero R, Wang E, Rodriguez AI,
Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM,
Garrido F, et al: Regression of melanoma metastases after
immunotherapy is associated with activation of antigen presentation
and interferon-mediated rejection genes. Int J Cancer. 131:387–395.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Randhawa J, Ostojic A, Vrhovac R, Atallah
E and Verstovsek S: Splenomegaly in myelofibrosis - new options for
therapy and the therapeutic potential of Janus kinase 2 inhibitors.
J Hematol Oncol. 5:432012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mathé E, Nguyen GH, Funamizu N, He P,
Moake M, Croce CM and Hussain SP: Inflammation regulates microRNA
expression in cooperation with p53 and nitric oxide. Int J Cancer.
131:760–765. 2012. View Article : Google Scholar : PubMed/NCBI
|
